Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection

  • Authors:
    • Rie Osaki
    • Takashi Nishimura
    • Makoto Shioya
    • Takayuki Takeuchi
    • Yoshiaki Okumura
    • Tamio Nakahara
    • Shigeki Bamba
    • Shinobu Nakajo
    • Yoshihide Fujiyama
    • Akira Andoh
  • View Affiliations

  • Published online on: November 1, 2011     https://doi.org/10.3892/mmr.2011.655
  • Pages:525-528
0

Abstract

We recently reported that the interleukin (IL)-28B major genotype is a predictor of early suppression of the hepatitis C virus (HCV) at 12 weeks in response to pegylated interferon (PEG-IFN) plus ribavirin (RBV) therapy. The present study investigated the relationship between IL-28 genotypes and the virological response to PEG-IFN/RBV therapy at 24 and 48 weeks. Genotypes of the IL-28B rs8099917 T>G single nucleotide polymorphism were determined in 177 patients with HCV infection. Among them, 56 patients with HCV1 infection were treated with PEG-IFN/RBV. The frequency of the IL-28B major allele (TT) was 73.8% in patients with HCV serotype 1 and 86.3% in patients with HCV serotype 2. The rate of HCV-RNA positivity was significantly lower at 48 weeks in patients with the IL-28B major allele compared to patients with the IL-28B minor allele (TG or GG). The rate of HCV-RNA positivity at 24 weeks tended to be lower in patients with the IL-28B major allele, but there was no statistical significance (P=0.059). The sustained virological response (SVR) rate was 45.9% in patients with the IL-28B major allele, but 13.3% in patients with the IL-28B minor allele. The SVR correlated with the IL-28B major allele (OR=7.13, P=0.010), early virological response (OR=33.3, P=0.008), HCV-RNA ≤6.3 log IU/ml (OR=81.2, P=0.009) and γ-GTP ≤47 IU/l (OR=49.4, P=0.027). The IL-28B genotype is a significant pre-treatment predictor of the response to PEG-IFN/RBV therapy at 48 weeks in patients with HCV infection.

Related Articles

Journal Cover

February 2012
Volume 5 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

2016 Impact Factor: 1.692
Ranked #19/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Osaki, R., Nishimura, T., Shioya, M., Takeuchi, T., Okumura, Y., Nakahara, T. ... Andoh, A. (2012). Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection. Molecular Medicine Reports, 5, 525-528. https://doi.org/10.3892/mmr.2011.655
MLA
Osaki, R., Nishimura, T., Shioya, M., Takeuchi, T., Okumura, Y., Nakahara, T., Bamba, S., Nakajo, S., Fujiyama, Y., Andoh, A."Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection". Molecular Medicine Reports 5.2 (2012): 525-528.
Chicago
Osaki, R., Nishimura, T., Shioya, M., Takeuchi, T., Okumura, Y., Nakahara, T., Bamba, S., Nakajo, S., Fujiyama, Y., Andoh, A."Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection". Molecular Medicine Reports 5, no. 2 (2012): 525-528. https://doi.org/10.3892/mmr.2011.655